Efficacy

Efficacy of Alunbrig (brigatinib) in Lung Cancer

Alunbrig (brigatinib) is a medication that has been approved for the treatment of non-small cell lung cancer (NSCLC) with specific genetic alterations, namely anaplastic lymphoma kinase (ALK) positive mutations. The efficacy of Alunbrig in treating this type of lung cancer was demonstrated in several clinical trials. One pivotal trial that led to its approval was the ALTA-1L study, which showed that brigatinib significantly improved progression-free survival compared to crizotinib, another ALK inhibitor, in patients with ALK-positive NSCLC who had not received prior treatment. Patients treated with brigatinib experienced a median progression-free survival of around 24 months, compared to approximately 11 months for those on crizotinib.

Additionally, brigatinib has shown high intracranial efficacy in patients with brain metastases, a common complication of ALK-positive NSCLC. In clinical trials, a substantial proportion of patients with measurable brain metastases at baseline achieved complete or partial responses, suggesting that Alunbrig is effective in controlling central nervous system disease, which is a significant concern in this patient population.

Efficacy of Gavreto (pralsetinib) in Lung Cancer

Gavreto (pralsetinib) is another targeted therapy approved for the treatment of NSCLC, specifically for patients with rearranged during transfection (RET) fusion-positive tumors. The approval of Gavreto was based on results from the ARROW clinical trial, which demonstrated that pralsetinib had significant antitumor activity in patients with RET fusion-positive NSCLC. The trial reported an overall response rate of approximately 70% in treatment-naive patients and around 60% in those who had undergone prior therapy, indicating that Gavreto is highly effective in inducing tumor responses in this patient population.

In addition to its efficacy in shrinking tumors, Gavreto has also shown a durable response, with many patients experiencing prolonged periods of disease control. This is particularly important for patients with RET fusion-positive NSCLC, as this genetic alteration is associated with a poor prognosis and limited treatment options. The introduction of Gavreto provides a new targeted therapy option that can lead to significant improvements in outcomes for these patients.